Testing ubamatamab for MUC16-positive rare cancers
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug, ubamatamab, alone or with another drug called cemiplimab, for people with rare cancers like renal medullary carcinoma or epithelioid sarcoma. These drugs help your immune system attack cancer cells that have a specific protein (MUC16).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a rare cancer called renal medullary carcinoma or epithelioid sarcoma
- Your tumor has lost a protein called SMARCB1 (confirmed by a lab test)
- Your cancer has spread or cannot be removed with surgery
- You must have a CA-125 blood test result of 70 or higher, or a tumor test showing MUC16 protein
- You have already tried at least one treatment that stopped working
- You are physically able to care for yourself (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called sacituzumab tirumotecan for a rare and aggressive type of kidney cancer called renal medullary carcinoma (RMC) or a related variant. The drug is designed to target and deliver treatment directly to cancer cells. The study aims to see if it can shrink tumors or slow the disease in people who have already tried other treatments.
This early-phase study tests ubamatamab, a cancer-targeting antibody, given by itself or with cemiplimab. It is meant to treat adults whose cancer has come back and who may not have other good standard options left.
This trial tests a new targeted therapy (ubamatamab) alone or with another drug (REGN7075) for people with advanced or metastatic non-small cell lung cancer that has gotten worse after standard treatment. It aims to see if targeting MUC16, a substance found on some cancer cells, can help control the cancer.
This study tests a new combination treatment (ubamatamab plus another drug) for people with ovarian cancer that no longer responds to platinum chemotherapy. It could be an option if your cancer has kept growing despite prior treatment.
This trial tests a new drug called ubamatamab combined with standard chemotherapy for advanced ovarian cancer that didn't respond well to initial treatment. It's designed for patients whose cancer is hard to remove surgically and didn't shrink enough with first-line chemotherapy.
This trial tests a new drug called CMAB017 for people with advanced solid tumors who have run out of standard options. The goal is to find a safe dose and see how well it is tolerated.
Hear when a new Epithelioid Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.